NRAS and melanoma: This combination is currently being evaluated in the ongoing Nautilus trial in patients with RAS pathway-mutated advanced solid tumors and NRAS-mutated melanomas (NCT05340621), with phase 2 data demonstrating there was a 38% overall response rate (ORR) in patients with metastatic NRAS-mutated melanoma previously treated with immunotherapy [34].